| Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy Y Chen, Y Huang, Q Li, Z Luo, Z Zhang, H Huang, J Sun, LXT Zhang, ... Nature nanotechnology 18 (2), 193-204, 2023 | 44 | 2023 |
| Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages P Moharil, Z Wan, A Pardeshi, J Li, H Huang, Z Luo, S Rathod, Z Zhang, ... Acta Pharmaceutica Sinica B 12 (3), 1148-1162, 2022 | 33 | 2022 |
| Mobilizing phospholipids on tumor plasma membrane implicates phosphatidylserine externalization blockade for cancer immunotherapy W Wang, S Wu, Z Cen, Y Zhang, Y Chen, Y Huang, AR Cillo, JS Prokopec, ... Cell reports 41 (5), 2022 | 20 | 2022 |
| A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death H Huang, Y Huang, Y Chen, Z Luo, Z Zhang, R Sun, Z Wan, J Sun, B Lu, ... Biomaterials 270, 120708, 2021 | 18 | 2021 |
| Genetic deficiency of MicroRNA‐15a/16‐1 confers resistance to neuropathological damage and cognitive dysfunction in experimental vascular cognitive impairment and dementia C Zhou, P Sun, Y Xu, Y Chen, Y Huang, MH Hamblin, L Foley, ... Advanced Science 9 (17), 2104986, 2022 | 14 | 2022 |
| Overcoming pancreatic cancer immune resistance by codelivery of CCR2 antagonist using a STING-activating gemcitabine-based nanocarrier Z Wan, H Huang, RE West III, M Zhang, B Zhang, X Cai, Z Zhang, Z Luo, ... Materials Today 62, 33-50, 2023 | 13 | 2023 |
| Guided delivery of the “alarming” cytokine IL-33 to tumor by chimeric antigen receptor T cells Y Chen, B Lu The Journal of Immunology 198 (1_Supplement), 204.23-204.23, 2017 | 9 | 2017 |
| Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1 Y Zhang, J Li, Y Huang, Y Chen, Z Luo, H Huang, RE West III, TD Nolin, ... Theranostics 13 (2), 578, 2023 | 7 | 2023 |
| Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination Y Chen, Y Huang, H Huang, Z Luo, Z Zhang, R Sun, Z Wan, J Sun, B Lu, ... Molecular Therapy-Nucleic Acids 26, 594-602, 2021 | 6 | 2021 |
| Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response Y Wang, Y Zhao, W Guo, GS Yadav, C Bhaskarla, Z Wang, X Wang, S Li, ... Science Advances 8 (49), eadd0005, 2022 | 5 | 2022 |
| In Situ Formation of Fibronectin‐Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy Z Luo, Z Wan, P Ren, B Zhang, Y Huang, RE West III, H Huang, Y Chen, ... Advanced Science 11 (19), 2307940, 2024 | 2 | 2024 |
| Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy Z Luo, Y Huang, N Batra, Y Chen, H Huang, Y Wang, Z Zhang, S Li, ... Nature Communications 15 (1), 255, 2024 | 2 | 2024 |
| Hepatocyte estrogen sulfotransferase inhibition protects female mice from concanavalin A–induced T cell–mediated hepatitis independent of estrogens J Wang, Z Zhang, J Guan, HC Tung, J Xie, H Huang, Y Chen, M Xu, ... Journal of Biological Chemistry 299 (3), 2023 | 2 | 2023 |
| Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment Y Chen, CY Chen, H Huang, Z Luo, Y Mu, S Li, Y Huang, S Li Journal of Controlled Release 370, 479-489, 2024 | | 2024 |
Zhangyi LuoUniversity of Pittsburgh在 pitt.edu 的电子邮件经过验证
